Compare ADT Inc (ADT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs TG Therapeutics Inc — how do they compare? ADT Inc trades at $7.32 (market cap $5.34B), while TG Therapeutics Inc trades at $48.92 (market cap $7.58B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and ADT Inc pays a 3.01% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ADT | TGTX | |
|---|---|---|
Market Cap | $5.34B | $7.58B |
Sector | Industrials | Health |
52-Week High | $8.85 | $59.06 |
52-Week Low | $6.30 | $26.94 |
Enterprise Value | $13.02B | $7.78B |
Dividend Yield | 3.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.33, down 2.4% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.23, beating estimates, and maintains strong cash flow. Valuation ratios appear attractive with a P/E of 10.35 and EV/EBITDA of 4.93. Recent news highlights a Zacks upgrade to Buy and institutional stake increases.
Outlook is positive due to consistent earnings beats and solid profitability, but risks include high debt levels and competitive pressures. Analysts are generally bullish, with 47% recommending Buy. The stock offers value with growth potential from AI integration and shareholder returns via dividends and buybacks.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
